Creative Medical Technology (CELZ) Expected to Announce Quarterly Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ) is expected to issue its resultson Friday, November 6th. Analysts expect Creative Medical Technology to post earnings of ($0.24) per share for the quarter.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, analysts expect Creative Medical Technology to post ($1.18) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Creative Medical Technology Price Performance

Creative Medical Technology stock opened at $0.67 on Wednesday. Creative Medical Technology has a fifty-two week low of $0.60 and a fifty-two week high of $4.72. The stock has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $1.56.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CELZ. Weiss Ratings downgraded Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.